Corrigendum to “Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme” [Blood Rev. 2023 Sep:61:101103] (Blood Reviews (2023) 61, (S0268960X23000644), (10.1016/j.blre.2023.101103))

Abstract

The authors regret that in the published article, a part of Table 2 titled ‘Main clinical study results of subjects treated with PK activators in hereditary hemolytic anemia’ was missing. A correction has therefore been made to Table 2 with the addition of the last three columns and some abbreviations in the legend. The original article has been updated. The authors would like to apologise for any inconvenience caused.